Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Allergy

Researchers make breakthrough in potential treatment for peanut allergy

If approved, the peanut protein-based drug will be the first therapeutic treatment for peanut allergy.

Peanut kernels and shell

Source: Shutterstock.com

Study participants could tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning

Children and young people with peanut allergy may be able to protect themselves from accidental ingestion by building up their tolerance to peanut protein over time, a study published in the New England Journal of Medicine (18 November 2018) has shown[1].

The phase III trial, the results of which were presented at the American College of Allergy, Asthma and Immunology (ACAAI) annual scientific meeting, included 551 participants aged 4–55 years, all of whom were highly allergic to peanuts. The participants were randomly assigned in a 3:1 ratio to receive either AR101 (a peanut-derived biologic drug with a characterised protein profile) or placebo.

The AR101 group received increasing amounts of peanut protein until they reached the “maintenance dose” of 300mg, equivalent to one peanut a day, on which they then remained for approximately 24 weeks.

The researchers then tested to see whether the participants could ingest a challenge dose of 600mg or more — the equivalent of approximately two whole peanut kernels — without dose-limiting symptoms.

Overall, 67% of the participants aged 4–17 years in the AR101 group could tolerate a single dose of at least 600mg of peanut protein at the end of the study, compared with 4% in the placebo group, despite the fact that none of them were able to tolerate more than 30mg of peanut protein prior to treatment.

“Reactions from the oral challenges at the end of the study were much milder than prior to treatment,” said Stephen Tilles, study co-author and former president of the ACAAI.

“On average, the participants were able to tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning. In addition, the symptoms caused by the 100-fold higher dose at the end of study were milder than the symptoms on the lower dose at the beginning of the study.”

However, no significant effect was found in participants aged 18–55 years.

Adverse events were common in the two trial groups. But adverse events that were considered by the investigators to be serious or severe occurred in fewer than 6% of the participants in the AR101 group and in fewer than 2% of those in the placebo group.

“This is not a quick fix, and it doesn’t mean people with peanut allergy will be able to eat peanuts whenever they want,” said Jay Lieberman, co-author and vice chair of the ACAAI Food Allergy Committee.

“But it is definitely a breakthrough. The hope would be to have a treatment available in the second half of 2019. If that happens, people who receive and are able to tolerate this treatment should be protected from accidental exposures.”

If this treatment is approved by the FDA, it will be available by prescription, and people with a peanut allergy will need to take it continuously to stay protected against accidental consumption, the researchers said. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205773

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.

    £35.00Buy now
  • Principles of Good Clinical Practice

    Principles of Good Clinical Practice

    A one-stop source for the proper conduct of clinical trials. Essential information on clinical trial design and pharmacovigilance.

    £49.00Buy now
  • Integrated Pharmacy Case Studies

    Integrated Pharmacy Case Studies

    Over 90 case studies based on real life patient-care scenarios. Each case includes learning outcomes and references.

    £47.00Buy now
  • Popular Medicines

    Popular Medicines

    An illustrated history of some of the most popular branded medicines. Includes colourful historical adverts and details of the medicine's formula and intended purpose.

    £22.00Buy now
  • Developing Your Prescribing Skills

    Developing Your Prescribing Skills

    Developing Your Prescribing Skills uses case studies, mind maps and feedback from experienced prescribers. It supplies practical advice on the issues facing prescribers in all types of practice.

    £23.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.